Biomarkers in Alzheimer's Disease

Overview

Journal Adv Lab Med

Publisher De Gruyter

Specialty Biochemistry

Date 2023 Jun 26

PMID 37359199

Authors

Manuel H Janeiro

Carlos G Ardanaz

Noemi Sola-Sevilla

Jinya Dong

Maria Cortes-Erice

Maite Solas

Elena Puerta

Maria J Ramirez

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease. AD is the main cause of dementia worldwide and aging is the main risk factor for developing the illness. AD classical diagnostic criteria rely on clinical data. However, the development of a biological definition of AD using biomarkers that reflect the underling neuropathology is needed.

Content: The aim of this review is to describe the main outcomes when measuring classical and novel biomarkers in biological fluids or neuroimaging.

Summary: Nowadays, there are three classical biomarkers for the diagnosis of AD: Aβ42, t-Tau and p-Tau. The diagnostic use of cerebrospinal fluid biomarkers is limited due to invasive collection by lumbar puncture with potential side effects. Plasma/serum measurements are the gold standard in clinics, because they are minimally invasive and, in consequence, easily collected and processed. The two main proteins implicated in the pathological process, Aβ and Tau, can be visualized using neuroimaging techniques, such as positron emission tomography.

Outlook: As it is currently accepted that AD starts decades before clinical symptoms could be diagnosed, the opportunity to detect biological alterations prior to clinical symptoms would allow early diagnosis or even perhaps change treatment possibilities.

Citing Articles

Impact of physical exercise on the regulation of brain-derived neurotrophic factor in people with neurodegenerative diseases.

Romero Garavito A, Diaz Martinez V, Juarez Cortes E, Negrete Diaz J, Montilla Rodriguez L Front Neurol. 2025; 15:1505879.

PMID: 39935805 PMC: 11810746. DOI: 10.3389/fneur.2024.1505879.

Preclinical Cognitive Markers of Alzheimer Disease and Early Diagnosis Using Virtual Reality and Artificial Intelligence: Literature Review.

Scribano Parada M, Gonzalez Palau F, Valladares Rodriguez S, Rincon M, Rico Barroeta M, Garcia Rodriguez M JMIR Med Inform. 2025; 13:e62914.

PMID: 39881486 PMC: 11793867. DOI: 10.2196/62914.

Human Endogenous Retroviruses in Neurodegenerative Diseases.

Adler G, Le K, Fu Y, Kim W Genes (Basel). 2024; 15(6).

PMID: 38927681 PMC: 11202925. DOI: 10.3390/genes15060745.

Data Mining of Microarray Datasets in Translational Neuroscience.

OConnor L, OConnor B, Zeng J, Lo C Brain Sci. 2023; 13(9).

PMID: 37759919 PMC: 10527016. DOI: 10.3390/brainsci13091318.

Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits.

Nikiforova A, Sedov I Int J Mol Sci. 2023; 24(13).

PMID: 37446329 PMC: 10342860. DOI: 10.3390/ijms241311152.

References

Pannee J, Tornqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G . The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease. Neurosci Lett. 2014; 573:7-12. DOI: 10.1016/j.neulet.2014.04.041. View

Palmqvist S, Scholl M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H . Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017; 8(1):1214. PMC: 5663717. DOI: 10.1038/s41467-017-01150-x. View

Klunk W . Molecular imaging: What is right and what is an illusion?. Alzheimers Dement (Amst). 2018; 10:217-220. PMC: 5956935. DOI: 10.1016/j.dadm.2018.01.004. View

Humpel C . Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol. 2010; 29(1):26-32. PMC: 3016495. DOI: 10.1016/j.tibtech.2010.09.007. View

Zhou J, Greicius M, Gennatas E, Growdon M, Jang J, Rabinovici G . Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain. 2010; 133(Pt 5):1352-67. PMC: 2912696. DOI: 10.1093/brain/awq075. View

Perez-Grijalba V, Fandos N, Canudas J, Insua D, Casabona D, Lacosta A . Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma. J Alzheimers Dis. 2016; 54(2):751-62. PMC: 5044780. DOI: 10.3233/JAD-160325. View

Gili T, Cercignani M, Serra L, Perri R, Giove F, Maraviglia B . Regional brain atrophy and functional disconnection across Alzheimer's disease evolution. J Neurol Neurosurg Psychiatry. 2010; 82(1):58-66. DOI: 10.1136/jnnp.2009.199935. View

Nagaraj S, Zoltowska K, Laskowska-Kaszub K, Wojda U . microRNA diagnostic panel for Alzheimer's disease and epigenetic trade-off between neurodegeneration and cancer. Ageing Res Rev. 2018; 49:125-143. DOI: 10.1016/j.arr.2018.10.008. View

Taoka T, Morikawa M, Akashi T, Miyasaka T, Nakagawa H, Kiuchi K . Fractional anisotropy--threshold dependence in tract-based diffusion tensor analysis: evaluation of the uncinate fasciculus in Alzheimer disease. AJNR Am J Neuroradiol. 2009; 30(9):1700-3. PMC: 7051508. DOI: 10.3174/ajnr.A1698. View

10.

Allen G, Barnard H, McColl R, Hester A, Fields J, Weiner M . Reduced hippocampal functional connectivity in Alzheimer disease. Arch Neurol. 2007; 64(10):1482-7. DOI: 10.1001/archneur.64.10.1482. View

11.

Preische O, Schultz S, Apel A, Kuhle J, Kaeser S, Barro C . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019; 25(2):277-283. PMC: 6367005. DOI: 10.1038/s41591-018-0304-3. View

12.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

13.

Nabers A, Perna L, Lange J, Mons U, Schartner J, Guldenhaupt J . Amyloid blood biomarker detects Alzheimer's disease. EMBO Mol Med. 2018; 10(5). PMC: 5938617. DOI: 10.15252/emmm.201708763. View

14.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

15.

Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E . Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2008; 31(3):357-67. DOI: 10.1016/j.neurobiolaging.2008.03.027. View

16.

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

17.

Graff-Radford N, Crook J, Lucas J, Boeve B, Knopman D, Ivnik R . Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007; 64(3):354-62. DOI: 10.1001/archneur.64.3.354. View

18.

Weston P, Poole T, Ryan N, Nair A, Liang Y, Macpherson K . Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017; 89(21):2167-2175. PMC: 5696646. DOI: 10.1212/WNL.0000000000004667. View

19.

Ship J, DeCarli C, Friedland R, Baum B . Diminished submandibular salivary flow in dementia of the Alzheimer type. J Gerontol. 1990; 45(2):M61-6. DOI: 10.1093/geronj/45.2.m61. View

20.

OBryant S, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S . Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement. 2014; 11(5):549-60. PMC: 4414664. DOI: 10.1016/j.jalz.2014.08.099. View